CSIMarket Company Name, Ticker, Customers, else..
 
Windtree Therapeutics Inc  (WINT)
 

Windtree Therapeutics Inc's Customers Performance

WINT


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
WINT's Source of Revenues

• List of WINT Customers




for the same period Windtree Therapeutics Inc

• List of WINT Customers

Windtree Therapeutics Inc's Business Units






Windtree Therapeutics Inc's Comment on Sales, Marketing and Customers



The company is developing istaroxime, a cardiovascular drug candidate intended for the treatment of early cardiogenic shock and acute heart failure (AHF). The target patient population includes individuals with severe heart failure, particularly those experiencing early cardiogenic shock characterized by low blood pressure and risk of hypoperfusion to critical organs. Istaroxime is designed for use in hospital settings where effective treatments for AHF are limited. Clinical goals include relieving pulmonary congestion and edema, improving cardiac function and organ perfusion, stabilizing patients, and facilitating their transition to outpatient therapies for chronic heart failure management. The company has received FDA Fast Track designation for istaroxime in the treatment of AHF. The focus is on high-risk patients with acute heart failure and early cardiogenic shock, especially those with low systolic blood pressure and peripheral hypoperfusion who present treatment challenges.


  News about Windtree Therapeutics Inc Contracts

Windtree Therapeutics Provides Update on IstaroximeClinical Development and Upcoming Clinical Trial Data

Windtree Therapeutics Advances Istaroxime Clinical Development with Promising Data Expected from SEISMiC Extension Phase 2b Study in Early Cardiogenic Shock Patients Windtree Therapeutics has made significant strides in the clinical development of Istaroxime, a promising therapy aimed at treating early cardiogenic shock (CS) patients. Recent updates from the company suggest that the SEISMiC Extension Phase 2b study is nearing the completion of its enrollment phase, instilling optimism about the potential therapeutic impact of Istaroxime in this critical patient population.Istaroxime operates through a unique mechanism that combines inotropic support enhancing the heart s ability to contract with a favorable...




Windtree Therapeutics Inc’s Comment on Sales, Marketing and Customers


The company is developing istaroxime, a cardiovascular drug candidate intended for the treatment of early cardiogenic shock and acute heart failure (AHF). The target patient population includes individuals with severe heart failure, particularly those experiencing early cardiogenic shock characterized by low blood pressure and risk of hypoperfusion to critical organs. Istaroxime is designed for use in hospital settings where effective treatments for AHF are limited. Clinical goals include relieving pulmonary congestion and edema, improving cardiac function and organ perfusion, stabilizing patients, and facilitating their transition to outpatient therapies for chronic heart failure management. The company has received FDA Fast Track designation for istaroxime in the treatment of AHF. The focus is on high-risk patients with acute heart failure and early cardiogenic shock, especially those with low systolic blood pressure and peripheral hypoperfusion who present treatment challenges.







WINT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Windtree Therapeutics Inc 0.01 0.73 -40.99 15
SUBTOTAL 0.00 0.00 0.00 -

Sources: Windtree Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Windtree Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Windtree Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.